Published

Next generation antidepressants with novel mechanisms for treatment resistant depression.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Unknown
Date: 2023-03-08
Source: Europe PMC
DOI: 10.1016/bs.pbr.2023.02.005
PubMed: 37414491

Authors

Chen MH Tu PC Su TP.

Watch author

Derived topics and classifications

psilocybin Depression Neuroplasticity Pharmacology Mechanism of Action Receptor Pharmacology Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-05 Psychedelics and mental health: reimagining care through science, insight, and compassionFrontiers in Pharmacology · 2025-09-02 Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimizationFrontiers in Psychiatry · 2025-04-07 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-04 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-12 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2019-12-31 The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-07-31